- Financial Times•5 hours ago
Anglo-Swedish drugmaker AstraZeneca is expanding its widely watched trials for durvalumab, a potential breakthrough treatment for several forms of cancer. The drug is among a group of therapies designed ...
- Barrons.com•6 days ago
As my colleague Johanna Bennett noted, comments made by President-elect Donald Trump today about the high prices of drugs, as well as the fact that so many are manufactured outside the U.S. has helped sink biotech and pharmaceutical stocks alike.
- MarketWatch•6 days ago
U.K. stocks record an all-time closing high for a 10 straight session on Wednesday as the pound moved deeper into negative territory and kept supporting shares of the country’s major exporters.
AZN.L : Summary for ASTRAZENECA PLC ORD SHS $0.25 - Yahoo Finance
AstraZeneca PLC (AZN.L)
LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
|Bid||4,500.00 x 6100|
|Ask||4,660.00 x 13000|
|Day's Range||4,529.00 - 4,688.01|
|52 Week Range||3,680.00 - 5,505.00|
|PE Ratio (TTM)||23.25|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|